Allison Betof Warner, MD, PhD
@drbetofmdphd.bsky.social
Director of Advanced Melanoma Program, Director of Solid Tumor Cell Therapy @StanfordCancer | @MGH Medicine/ @MSKCC Onc Alum | wife/dog mom🐾 | Philadelphia sports phanatic | CF-L2
The patient population is very small here. It’s only for synovial sarcoma, HLA A02+ (because it is a TCR) and MAGE A4 positive. It made sense to start small and expand from there. More centers are coming on board!
March 26, 2025 at 3:51 AM
The patient population is very small here. It’s only for synovial sarcoma, HLA A02+ (because it is a TCR) and MAGE A4 positive. It made sense to start small and expand from there. More centers are coming on board!
Reposted by Allison Betof Warner, MD, PhD
...and more of our amazing #ESMO #IOTECH Editorial Board members:
@drbetofmdphd.bsky.social
@dgfeller.bsky.social
@kevlitchfield.bsky.social
@artkrieg.bsky.social
@bertrandrouty.bsky.social
@charlesswanton.bsky.social
@pamsharmamdphd.bsky.social
🦋 Follow for insights into #CancerImmunology!
@drbetofmdphd.bsky.social
@dgfeller.bsky.social
@kevlitchfield.bsky.social
@artkrieg.bsky.social
@bertrandrouty.bsky.social
@charlesswanton.bsky.social
@pamsharmamdphd.bsky.social
🦋 Follow for insights into #CancerImmunology!
December 12, 2024 at 7:30 PM
...and more of our amazing #ESMO #IOTECH Editorial Board members:
@drbetofmdphd.bsky.social
@dgfeller.bsky.social
@kevlitchfield.bsky.social
@artkrieg.bsky.social
@bertrandrouty.bsky.social
@charlesswanton.bsky.social
@pamsharmamdphd.bsky.social
🦋 Follow for insights into #CancerImmunology!
@drbetofmdphd.bsky.social
@dgfeller.bsky.social
@kevlitchfield.bsky.social
@artkrieg.bsky.social
@bertrandrouty.bsky.social
@charlesswanton.bsky.social
@pamsharmamdphd.bsky.social
🦋 Follow for insights into #CancerImmunology!